Physician profile
Ihab Hammoud
NPI 1538378617
$3,089.50
in general payments reported to CMS, 2019-2025
17 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.14 · 2022: $278 · 2023: $535 · 2024: $598 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.36 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.99 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.97 | 2024-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $413.87 | 2022-2025 | Entyvio, Gattex |
| Aimmune Therapeutics, INC. | $407.94 | 2024-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $246.47 | 2025 | Tremfya, Stelara, Simponi Aria |
| Daiichi Sankyo INC. | $224.89 | 2022-2024 | Injectafer |
| Ardelyx, INC. | $205.92 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $130.00 | 2023 | Libtayo |
| Otsuka America Pharmaceutical, INC. | $124.55 | 2025 | Rexulti |
| Ipsen Biopharmaceuticals, INC | $100.47 | 2023-2025 | Bylvay, Iqirvo |
| Celgene Corporation | $85.14 | 2023 | Zeposia |
| Qol Medical, LLC | $50.43 | 2025 | Sucraid |
| Lilly USA, LLC | $41.12 | 2024-2025 | Omvoh |
| Fresenius Kabi USA, LLC | $20.31 | 2024 | Idacio |
| Medtronic, INC. | $19.69 | 2023 | Interstim |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.60 | 2025 | Wegovy |
| Boston Scientific Corporation | $18.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihab Hammoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.